精密疗法出席第33届年度圣安东尼奥乳癌研讨会

Precision Therapeutics to Present Abstracts at 33rd Annual San Antonio Breast Cancer Symposium

精密疗法出席第33届年度圣安东尼奥乳癌研讨会

print this article - email to a friend - join our eNewsletter

Submitted by admin on 11/30/2010 @ 10:00 PM

Companies mentioned in this article: Precision Therapeutics

在这篇文章中提到的公司：精密治疗

PITTSBURGH, Dec. 1, 2010 /PRNewswire/ -- Precision Therapeutics will present two abstracts at the 33rd Annual San Antonio Breast Cancer Symposium, which will be held December 8-12, 2010 in San Antonio, Texas.

匹兹堡，2010年12月1日/新华美通/ - 精密治疗将在第33届圣安东尼奥乳癌研讨会上提出二个概念，这个会议将在2010年十二月8号至12号的德克萨斯州的圣安东尼奥举办。

Using immortalized breast cancer cell lines and the ChemoFx® Drug Response Marker, the abstract titled, 'Feasibility Assessment of Pharmacogenomic Predictors Developed from Breast Cancer Cell Lines to Predict Breast Cancer Patient Pathological Response in Neoadjuvant Chemotherapy,' demonstrates the feasibility of using cell-line based multi-gene predictors for predicting pathologic complete response in patients, based on their genomic profiles.

使用永生的乳腺癌细胞株和ChemoFx ®药物反应的标记,标题摘要.

“开发可行性评估药物基因预测乳腺癌细胞株中预测乳腺癌患者新辅助化疗病理反应”. 演示了用细胞系预测病理完全缓解的患者，其基因资料为基础的多基因预测的可行性。

A second abstract, titled, 'Pharmacogenomic Predictors of Patient Response to Chemotherapy Derived from Breast Cancer Cell Lines Combining Knowledge-Based and Data-Driven Methods,' has also been selected for poster presentation at the symposium and describes a unique method for incorporating pathway enrichment analysis in developing multi-gene predictors of chemotherapeutic response, further enhancing the biological relevance of the genes identified in the predictors.

第二个标题摘要，题目是“病人的反应的药物基因预测乳腺癌细胞系的配合知识型和数据驱动方法对化疗的结果，以”也被选定为海报在研讨会上介绍，并介绍纳入一个独特的方法途径分析发展化疗反应多基因的预测，进一步增强了在预测因子的相关基因生物。

Results described in both abstracts indicate the potential utility of genomic predictors in forecasting individual patient response to chemotherapy.

结果表明摘要中描述的预测个别患者对化疗反应的基因组预测潜在效用。

'We are very pleased and honored to be presenting these two abstracts at the SABCS meeting. Having this research accepted for publication is a tremendous milestone for cancer patients as well as for the advancement of genomic research in personalized medicine,' said Kui Shen, Bioinformatics Scientist at Precision Therapeutics.

我们非常高兴和荣幸，在SABCS会议提出这两个概念的摘要。这项研究是一个巨大的里程碑，为癌症病人在个性化药物基因组研究取得更进一步”，沈逵，精密治疗的生物信息学科学家。

About Precision Therapeutics  

关于精密治疗

Precision Therapeutics, a life-science company based in Pittsburgh, Pennsylvania, is committed to improving outcomes of cancer patients. As leaders in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer.

精密治疗，一个在宾夕法尼亚州匹兹堡的生命科学公司，致力于改善癌症病人的治疗。如个别差异，是通过独特的专有和活组织的癌症治疗平台使用学科带头人，开发新的精确方法，对每个人的癌症治疗过程进行指导帮助和决策.

Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offer an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy. Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. For more information, please visit www.precisiontherapeutics.com, or www.chemofx.com.

精密的最先进的生物信息学与生命分子分析的艺术组合, 为每个癌症病人蛋白质和基因组的活力提供一个创新的商业化的癌症治疗新的预测指标基础.

精密的第一个商业试验(ChemoFx ®)，是一种专利药物的反应指标衡量一个人的恶性肿瘤回答正在审议的标准治疗方案。欲了解更多信息，请访问 www.precisiontherapeutics.com, or www.chemofx.com.

SOURCE Precision Therapeutics.

精密治疗提供.